Results 171 to 180 of about 81,640 (291)

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

British Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen, Tamás Kovács, Péter Ferdinandy, Zoltán V. Varga   +3 more
wiley   +1 more source

Diagnostic role of galanin in distinguishing endometrial atypical hyperplasia and carcinoma from benign endometrial conditions. [PDF]

Sci Rep
Ata C, Bildaci TB, Atlihan U, Avsar HA, Erkilinc S.   +4 more
europepmc   +1 more source

Comparative Analysis of a Dual DNA–RNA Panel and a DNA‐Only Panel for Sarcoma: Real‐World Data From a Nationwide Genomic Database

Cancer Science, EarlyView.
Dual DNA–RNA panel with matched tumor–normal testing may improve diagnostic accuracy and inform treatment decisions in the routine clinical management of sarcoma. ABSTRACT Next‐generation sequencing‐based comprehensive cancer genomic profiling is promising in cancer management; however, most studies rely on tumor‐only DNA panels from single ...
Eiji Nakata, Kiichiro Ninomiya, Tatsunori Osone, Daisuke Ennishi, Shuta Tomida, Tomohiro Fujiwara, Toshiyuki Kunisada, Mashu Futagawa, Akira Hirasawa, Shinichi Toyooka, Toshifumi Ozaki   +10 more
wiley   +1 more source

Ureteral Recurrence of the Endometrial Cancer: A Case Report. [PDF]

Case Rep Med
Yuki H, Yokoyama M, Yamaguchi T, Yamaguchi S, Kamai T.   +4 more
europepmc   +1 more source

Prognostic Biomarker of Fertility‐Preserving Hormonal Therapy Based on Multigene Panel Testing for Endometrial Cancer

Cancer Science, EarlyView.
We identified prognostic biomarkers that predict treatment outcomes in patients receiving fertility‐preserving high‐dose medroxyprogesterone acetate (MPA) therapy through comprehensive multigene panel testing. ABSTRACT In this study, we identified prognostic biomarkers that predict treatment outcome in patients receiving fertility‐preserving high‐dose ...
Takuro Hirano, Kensuke Sakai, Takuma Yoshimura, Tatsuyuki Chiyoda, Kohei Nakamura, Eriko Aimono, Miho Kawaida, Hiroshi Nishihara, Nobuyuki Susumu, Daisuke Aoki, Wataru Yamagami   +10 more
wiley   +1 more source

Low-grade endometrial stromal sarcoma arising from extrauterine deep infiltrating endometriosis: a rare, but important differential diagnosis and short review of the literature. [PDF]

Gynecol Oncol Rep
Schiestl LJ, Schadmand-Fischer S, Tagkalos E, Raab U, Baqué PE, Hamscho N, Kommoss F, Jung D, Linz V, Schmidt M, Hasenburg A, Schwab R.   +11 more
europepmc   +1 more source

Update on Menopause Hormone Therapy; Current Indications and Unanswered Questions

Clinical Endocrinology, EarlyView.
ABSTRACT Objective To provide clinicians involved in managing menopause with a summary of current evidence surrounding menopause hormone therapy (MHT). Design The authors evaluate and synthesize existing pooled evidence relating to MHT's clinical indications, efficacy, and safety and explore the limitations of existing data. Patients The review focuses
Annice Mukherjee, Susan R. Davis
wiley   +1 more source

New histopathological and molecular findings in gynecological cancers. [PDF]

Int J Gynaecol Obstet
McCluggage WG.
europepmc   +1 more source

Mixed Gonadal Dysgenesis: A Comprehensive Review of Clinical Spectrum, Diagnostic Strategies, and Management Approaches

Clinical Endocrinology, EarlyView.
ABSTRACT Background Mixed gonadal dysgenesis (MGD) is a rare form of differences in sex development (DSD) typically associated with 45,X/46,XY mosaicism. The phenotypic presentation of MGD varies from atypical genitalia to typical male or female appearances often associated with Turner stigmata.
Dinesh Giri, Sushil Yewale, Hannah Hickingbotham, Cara Williams, Mohamed Shalaby, Julie Alderson, Julie Park   +6 more
wiley   +1 more source

DDIAS promotes endometrial cancer progression via β-catenin signaling. [PDF]

PLoS One
Tian X, Liu M, Zhao J, Lao C, Liu B, Suo Y.   +5 more
europepmc   +1 more source